Hutchison China MediTechの従業員
Hutchison China MediTechの従業員は何ですか。
Hutchison China MediTech Ltd.の従業員は1,280です。
従業員の定義は何ですか。
従業員は、従業員がやっている仕事の種類や自分が働いている仕事の種類に応じて、1時間ごとの賃金の形でもピザワークや年間給与の形でもよい支払いの代償として働きます。
Employment is a relationship between two parties, usually based on a contract where work is paid for, where one party, which may be a corporation, for profit, not-for-profit organization, co-operative or other entity is the employer and the other is the employee.
Employees in some fields or sectors may receive gratuities, bonus payment or stock options. In some types of employment, employees may receive benefits in addition to payment. Benefits can include health insurance, housing, disability insurance or use of a gym. Employment is typically governed by employment laws or regulations or legal contracts.
LSEのセクタHealth Careにおける従業員の企業と比べるHutchison China MediTech
Hutchison China MediTechは何をしますか。
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases worldwide. It operates in two segments, Oncology/Immunology and Other Ventures. It manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical, and consumer health products. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and clear cell renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, an inhibitor for indolent non-Hodgkin's lymphoma (NHL), B-cell malignancies, and immune thrombocytopenic purpura; and HMPL-689 for indolent non-Hodgkin's, follicular, marginal zone, mantle cell, diffuse large B cell, chronic lymphocytic leukemia/small lymphocytic, and Hodgkin's lymphoma. The company develops HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-295 for solid tumors; and HMPL-813 and HMPL-309 EGFR inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics (Suzhou) Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Central, Hong Kong.
Hutchison China MediTechと類似の従業員
- Insecticides (India)の従業員は1,276です。
- Munjal Auto Industriesの従業員は1,278です。
- Canfor Pulp Productsの従業員は1,278です。
- Genesys Internationalの従業員は1,278です。
- Seshasayee Paper and Boardsの従業員は1,278です。
- Forum Technologies Incの従業員は1,279です。
- Hutchison China MediTechの従業員は1,280です。
- Hindustan Media Venturesの従業員は1,281です。
- Universal Electronicsの従業員は1,281です。
- Irsa Inversiones Y Representaciones S.Aの従業員は1,281です。
- Capitalの従業員は1,282です。
- TransAltaの従業員は1,282です。
- AstraZeneca Pharma Indiaの従業員は1,283です。